Skip to main content
. 2014 Apr 21;20(15):4370–4376. doi: 10.3748/wjg.v20.i15.4370

Table 2.

Treatment modality of the patients n (%)

BRAF wild-type (n = 123) BRAF Mutant (n = 13) P value
Surgery 0.737
Yes 93 (75.6) 9 (69.2)
No 30 (24.4) 4 (30.8)
Chemotherapy
Yes 119 (96.7) 11 (84.6)
No 4 (3.3) 2 (15.4)
Chemotherapy regimen 0.441
FOLFOX 97 (82.2) 9 (81.8)
FOLFIRI 5 (4.2) 0
FL 7 (5.9) 2 (15.4)
Xeloda 8 (6.8) 0
SOX 1 (0.8) 0
Target agent use 0.128
No 91 (74.0) 8 (61.5)
Bevacizumab 19 (15.4) 5 (38.5)
Cetuximab 13 (10.6) 0